Orexo
17,54 SEK -15,67%Vær den første som følger denne virksomhed
Orexo is a Swedish pharmaceutical company that develops medicines based on proprietary formulation technologies that meet major medical needs. In the US market, Orexo offers treatment solutions for patients suffering from opioid addiction and related diseases. Products targeting other therapeutic areas are developed and commercialized worldwide in collaboration with partners. The head office, where the research and development work is conducted, is located in Uppsala.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
ORX
Daglig lav / høj pris
16,82 / 18,18
SEK
Markedsværdi
608,82 mio. SEK
Aktieomsætning
2,69 mio. SEK
Volumen
154 t
Seneste videoer
Finanskalender
Delårsrapport
17.07.2024
Delårsrapport
14.11.2024
Årsrapport
06.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Novo A/S | 27,8 % | 27,8 % |
Avanza Pension | 6,6 % | 6,6 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Orexo Q2 2024 Interim Report
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools